

Benjamin W Van Tassell

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7510334/benjamin-w-van-tassell-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

139
papers

5,898
citations

45
h-index

73
g-index

167
ext. papers

7,682
ext. citations

5.4
avg. IF

5.89
L-index

#	Paper	IF	Citations
139	The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 19725-30	11.5	403
138	Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). <i>American Journal of Cardiology</i> , 2010 , 105, 1371-1377.e1	3	279
137	Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 325, 1626-1636	27.4	235
136	Targeting interleukin-1 in heart disease. <i>Circulation</i> , 2013 , 128, 1910-23	16.7	202
135	Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. <i>Nature Reviews Immunology</i> , 2021 , 21, 319-329	36.5	192
134	A novel pharmacologic inhibitor of the NLRP3 inflammasome limits myocardial injury after ischemia-reperfusion in the mouse. <i>Journal of Cardiovascular Pharmacology</i> , 2014 , 63, 316-322	3.1	180
133	Anti-inflammatory strategies for ventricular remodeling following ST-segment elevation acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 1593-603	15.1	177
132	Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease. <i>Circulation Research</i> , 2020 , 126, 1260-1280	15.7	165
131	Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure. <i>PLoS ONE</i> , 2012 , 7, e33438	3.7	145
130	Inhibition of the NLRP3 inflammasome limits the inflammatory injury following myocardial ischemia-reperfusion in the mouse. <i>International Journal of Cardiology</i> , 2016 , 209, 215-20	3.2	137
129	Metabolic gene remodeling and mitochondrial dysfunction in failing right ventricular hypertrophy secondary to pulmonary arterial hypertension. <i>Circulation: Heart Failure</i> , 2013 , 6, 136-44	7.6	134
128	Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure: Results From REDHART (Recently Decompensated Heart Failure Anakinra Response Trial). <i>Circulation: Heart Failure</i> , 2017 , 10,	7.6	114
127	Alpha-1 antitrypsin inhibits caspase-1 and protects from acute myocardial ischemia-reperfusion injury. <i>Journal of Molecular and Cellular Cardiology</i> , 2011 , 51, 244-51	5.8	108
126	Pharmacologic Inhibition of the NLRP3 Inflammasome Preserves Cardiac Function After Ischemic and Nonischemic Injury in the Mouse. <i>Journal of Cardiovascular Pharmacology</i> , 2015 , 66, 1-8	3.1	100
125	Interleukin-18 mediates interleukin-1-induced cardiac dysfunction. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2014 , 306, H1025-31	5.2	88
124	Interleukin-18 as a therapeutic target in acute myocardial infarction and heart failure. <i>Molecular Medicine</i> , 2014 , 20, 221-9	6.2	86
123	Interleukin-1beta modulation using a genetically engineered antibody prevents adverse cardiac remodeling following acute myocardial infarction in the mouse. <i>European Journal of Heart Failure</i> , 2010 , 12, 319-22	12.3	86

122	Induction of microRNA-21 with exogenous hydrogen sulfide attenuates myocardial ischemic and inflammatory injury in mice. <i>Circulation: Cardiovascular Genetics</i> , 2014 , 7, 311-20		84
121	Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 1903-1921	15.1	84
120	Omega-3 Red Blood Cell Content Is Associated with Fat Mass Index and Leptin in Subjects with Obesity and Heart Failure with Preserved Ejection Fraction (P21-001-19). <i>Current Developments in Nutrition</i> , 2019 , 3,	0.4	78
119	Time of Eating and Cardiorespiratory Fitness in Patients with Heart Failure With Preserved Ejection Fraction and Obesity. <i>Current Developments in Nutrition</i> , 2021 , 5, 465-465	0.4	78
118	IL-1 Blockade in Patients With Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2018 , 11, e005036	7.6	76
117	Interleukin-1 β induces a reversible cardiomyopathy in the mouse. <i>Inflammation Research</i> , 2013 , 62, 637-40	0.2	75
116	Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP. <i>Diabetes Care</i> , 2017 , 40, 1733-1738	14.6	73
115	Heart failure with preserved ejection fraction: refocusing on diastole. <i>International Journal of Cardiology</i> , 2015 , 179, 430-40	3.2	73
114	Interleukin-1 β blockade improves cardiac remodeling after myocardial infarction without interrupting the inflammasome in the mouse. <i>Experimental Physiology</i> , 2013 , 98, 734-45	2.4	73
113	Interleukin-1 Blockade in Acute Decompensated Heart Failure: A Randomized, Double-Blinded, Placebo-Controlled Pilot Study. <i>Journal of Cardiovascular Pharmacology</i> , 2016 , 67, 544-51	3.1	73
112	Interleukin-1 Blockade Inhibits the Acute Inflammatory Response in Patients With ST-Segment-Elevation Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2020 , 9, e014941 ⁶		64
111	Galectin-1 controls cardiac inflammation and ventricular remodeling during acute myocardial infarction. <i>American Journal of Pathology</i> , 2013 , 182, 29-40	5.8	64
110	Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies. <i>Frontiers in Immunology</i> , 2020 , 11, 1625	8.4	64
109	Interleukin-1 trap attenuates cardiac remodeling after experimental acute myocardial infarction in mice. <i>Journal of Cardiovascular Pharmacology</i> , 2010 , 55, 117-22	3.1	62
108	Silencing of hypoxia-inducible factor-1 β gene attenuated angiotensin II-induced renal injury in Sprague-Dawley rats. <i>Hypertension</i> , 2011 , 58, 657-64	8.5	61
107	Interleukin-1 β blockade improves left ventricular systolic/diastolic function and restores contractility reserve in severe ischemic cardiomyopathy in the mouse. <i>Journal of Cardiovascular Pharmacology</i> , 2014 , 64, 1-6	3.1	57
106	Targeting interleukin-1 in heart failure and inflammatory heart disease. <i>Current Heart Failure Reports</i> , 2015 , 12, 33-41	2.8	56
105	Iloprost reverses established fibrosis in experimental right ventricular failure. <i>European Respiratory Journal</i> , 2015 , 45, 449-62	13.6	54

104	Blocking interleukin-1 as a novel therapeutic strategy for secondary prevention of cardiovascular events. <i>BioDrugs</i> , 2012 , 26, 217-33	7.9	53
103	Alterations in the interleukin-1/interleukin-1 receptor antagonist balance modulate cardiac remodeling following myocardial infarction in the mouse. <i>PLoS ONE</i> , 2011 , 6, e27923	3.7	53
102	Treatment of group I pulmonary arterial hypertension with carvedilol is safe. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014 , 189, 1562-4	10.2	52
101	Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 326, 230-239	27.4	51
100	The NLRP3 Inflammasome Inhibitor, OLT1177 (Dapansutrile), Reduces Infarct Size and Preserves Contractile Function After Ischemia Reperfusion Injury in the Mouse. <i>Journal of Cardiovascular Pharmacology</i> , 2019 , 73, 215-222	3.1	51
99	IL-1 Blockade Reduces Inflammation in Pulmonary Arterial Hypertension and Right Ventricular Failure: A Single-Arm, Open-Label, Phase IB/II Pilot Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019 , 199, 381-384	10.2	51
98	A high-sugar and high-fat diet impairs cardiac systolic and diastolic function in mice. <i>International Journal of Cardiology</i> , 2015 , 198, 66-9	3.2	50
97	Independent roles of the priming and the triggering of the NLRP3 inflammasome in the heart. <i>Cardiovascular Research</i> , 2015 , 105, 203-12	9.9	50
96	Formation of the inflammasome in acute myocarditis. <i>International Journal of Cardiology</i> , 2014 , 171, e119-21	3.2	49
95	GS-6201, a selective blocker of the A2B adenosine receptor, attenuates cardiac remodeling after acute myocardial infarction in the mouse. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012 , 343, 587-95	4.7	47
94	Pharmacologic inhibition of myeloid differentiation factor 88 (MyD88) prevents left ventricular dilation and hypertrophy after experimental acute myocardial infarction in the mouse. <i>Journal of Cardiovascular Pharmacology</i> , 2010 , 55, 385-90	3.1	45
93	Interleukin-1 blockade in heart failure with preserved ejection fraction: rationale and design of the Diastolic Heart Failure Anakinra Response Trial 2 (D-HART2). <i>Clinical Cardiology</i> , 2017 , 40, 626-632	3.3	42
92	Obesity Contributes to Exercise Intolerance in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 2487-2488	15.1	37
91	Usefulness of Canakinumab to Improve Exercise Capacity in Patients With Long-Term Systolic Heart Failure and Elevated C-Reactive Protein. <i>American Journal of Cardiology</i> , 2018 , 122, 1366-1370	3	35
90	Inhibition of apoptosis signal-regulating kinase 1 reduces myocardial ischemia-reperfusion injury in the mouse. <i>Journal of the American Heart Association</i> , 2012 , 1, e002360	6	35
89	Comparative cardiac toxicity of anthracyclines in vitro and in vivo in the mouse. <i>PLoS ONE</i> , 2013 , 8, e58421	3.7	35
88	Low NT-proBNP levels in overweight and obese patients do not rule out a diagnosis of heart failure with preserved ejection fraction. <i>ESC Heart Failure</i> , 2018 , 5, 372-378	3.7	33
87	Inflammatory markers in ST-elevation acute myocardial infarction. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2016 , 5, 382-95	4.3	33

86	Cardiovascular Considerations in Treating Patients With Coronavirus Disease 2019 (COVID-19). <i>Journal of Cardiovascular Pharmacology</i> , 2020 , 75, 359-367	3.1	33
85	Dietary Bioactive Fatty Acids as Modulators of Immune Function: Implications on Human Health. <i>Nutrients</i> , 2019 , 11,	6.7	33
84	Interleukin-1 blockade for the treatment of pericarditis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018 , 4, 46-53	6.4	32
83	Rationale and design of the Virginia Commonwealth University-Anakinra Remodeling Trial-3 (VCU-ART3): A randomized, placebo-controlled, double-blinded, multicenter study. <i>Clinical Cardiology</i> , 2018 , 41, 1004-1008	3.3	32
82	Dietary Fat, Sugar Consumption, and Cardiorespiratory Fitness in Patients With Heart Failure With Preserved Ejection Fraction. <i>JACC Basic To Translational Science</i> , 2017 , 2, 513-525	8.7	31
81	Nutrition and heart failure: impact of drug therapies and management strategies. <i>Nutrition in Clinical Practice</i> , 2009 , 24, 60-75	3.6	30
80	Right ventricular dysfunction following acute myocardial infarction in the absence of pulmonary hypertension in the mouse. <i>PLoS ONE</i> , 2011 , 6, e18102	3.7	30
79	A review of PCSK9 inhibition and its effects beyond LDL receptors. <i>Journal of Clinical Lipidology</i> , 2016 , 10, 1073-80	4.9	30
78	Recombinant human interleukin-1 receptor antagonist provides cardioprotection during myocardial ischemia reperfusion in the mouse. <i>Cardiovascular Drugs and Therapy</i> , 2012 , 26, 273-6	3.9	29
77	Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial. <i>Lancet Rheumatology, The</i> , 2021 , 3, e410-e418	14.2	29
76	A mouse model of heart failure with preserved ejection fraction due to chronic infusion of a low subpressor dose of angiotensin II. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2015 , 309, H771-8	5.2	28
75	A mouse model of radiation-induced cardiomyopathy. <i>International Journal of Cardiology</i> , 2012 , 156, 231-3	3.2	27
74	Aliskiren for renin inhibition: a new class of antihypertensives. <i>Annals of Pharmacotherapy</i> , 2007 , 41, 456-64	2.9	26
73	Phase 1B, Randomized, Double-Blinded, Dose Escalation, Single-Center, Repeat Dose Safety and Pharmacodynamics Study of the Oral NLRP3 Inhibitor Dapansutril in Subjects With NYHA II-III Systolic Heart Failure. <i>Journal of Cardiovascular Pharmacology</i> , 2020 , 77, 49-60	3.1	25
72	Altered oxido-reductive state in the diabetic heart: loss of cardioprotection due to protein disulfide isomerase. <i>Molecular Medicine</i> , 2011 , 17, 1012-21	6.2	23
71	Pharmacologic inhibition of phosphoinositide 3-kinase gamma (PI3K) promotes infarct resorption and prevents adverse cardiac remodeling after myocardial infarction in mice. <i>Journal of Cardiovascular Pharmacology</i> , 2010 , 56, 651-8	3.1	22
70	Effect of intensive blood pressure control in patients with type 2 diabetes mellitus over 9 years of follow-up: A subgroup analysis of high-risk ACCORDION trial participants. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 1499-1502	6.7	21
69	Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial. <i>Thrombosis and Haemostasis</i> , 2021 ,	7	21

68	Low-Density Lipoprotein Receptor-Related Protein-1 Is a Therapeutic Target in Acute Myocardial Infarction. <i>JACC Basic To Translational Science</i> , 2017 , 2, 561-574	8.7	20
67	Effectiveness of a Pharmacist-Physician Team-Based Collaboration to Improve Long-Term Blood Pressure Control at an Inner-City Safety-Net Clinic. <i>Pharmacotherapy</i> , 2016 , 36, 342-7	5.8	18
66	Role of Interleukin-1 in Radiation-Induced Cardiomyopathy. <i>Molecular Medicine</i> , 2015 , 21, 210-8	6.2	18
65	Clinical Presentation and Outcomes of Acute Pericarditis in a Large Urban Hospital in the United States of America. <i>Chest</i> , 2020 , 158, 2556-2567	5.3	17
64	Relation of Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease to Left Ventricular Diastolic Function and Exercise Tolerance. <i>American Journal of Cardiology</i> , 2019 , 123, 466-473	3	17
63	Unsaturated Fatty Acids to Improve Cardiorespiratory Fitness in Patients With Obesity and HFpEF: The UFA-Preserved Pilot Study. <i>JACC Basic To Translational Science</i> , 2019 , 4, 563-565	8.7	16
62	Interleukin-1 blockade in rheumatoid arthritis and heart failure: a missed opportunity?. <i>International Journal of Cardiology</i> , 2014 , 171, e125-6	3.2	16
61	Recombinant Human Alpha-1 Antitrypsin-Fc Fusion Protein Reduces Mouse Myocardial Inflammatory Injury After Ischemia-Reperfusion Independent of Elastase Inhibition. <i>Journal of Cardiovascular Pharmacology</i> , 2016 , 68, 27-32	3.1	16
60	Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective. <i>Cardiovascular Drugs and Therapy</i> , 2021 , 35, 249-259	3.9	16
59	Pharmacist-physician collaborative care model and time to goal blood pressure in the uninsured population. <i>Journal of Clinical Hypertension</i> , 2018 , 20, 88-95	2.3	14
58	An Orally Available NLRP3 Inflammasome Inhibitor Prevents Western Diet-Induced Cardiac Dysfunction in Mice. <i>Journal of Cardiovascular Pharmacology</i> , 2018 , 72, 303-307	3.1	14
57	Metabolic modulation predicts heart failure tests performance. <i>PLoS ONE</i> , 2019 , 14, e0218153	3.7	13
56	Effects of empagliflozin on cardiorespiratory fitness and significant interaction of loop diuretics. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2014-2018	6.7	13
55	Impaired myocardial relaxation with exercise determines peak aerobic exercise capacity in heart failure with preserved ejection fraction. <i>ESC Heart Failure</i> , 2017 , 4, 351-355	3.7	13
54	Parecoxib inhibits apoptosis in acute myocardial infarction due to permanent coronary ligation but not due to ischemia-reperfusion. <i>Journal of Cardiovascular Pharmacology</i> , 2009 , 53, 495-8	3.1	13
53	Intracellular function of interleukin-1 receptor antagonist in ischemic cardiomyocytes. <i>PLoS ONE</i> , 2013 , 8, e53265	3.7	12
52	Determinants of Cardiorespiratory Fitness Following Thoracic Radiotherapy in Lung or Breast Cancer Survivors. <i>American Journal of Cardiology</i> , 2020 , 125, 988-996	3	12
51	Effect of Interleukin-1 Blockade on Left Ventricular Systolic Performance and Work: A Post Hoc Pooled Analysis of 2 Clinical Trials. <i>Journal of Cardiovascular Pharmacology</i> , 2018 , 72, 68-70	3.1	11

50	Pharmacokinetics of L-Triiodothyronine in Patients Undergoing Thyroid Hormone Therapy Withdrawal. <i>Thyroid</i> , 2019 , 29, 1371-1379	6.2	11
49	Acute Effects of Interleukin-1 Blockade Using Anakinra in Patients With Acute Pericarditis. <i>Journal of Cardiovascular Pharmacology</i> , 2020 , 76, 50-52	3.1	11
48	Alirocumab in Acute Myocardial Infarction: Results From the Virginia Commonwealth University Alirocumab Response Trial (VCU-AlirocRT). <i>Journal of Cardiovascular Pharmacology</i> , 2019 , 74, 266-269	3.1	11
47	Unsupervised analysis of combined lipid and coagulation data reveals coagulopathy subtypes among dialysis patients. <i>Journal of Lipid Research</i> , 2017 , 58, 586-599	6.3	10
46	The effects of canagliflozin compared to sitagliptin on cardiorespiratory fitness in type 2 diabetes mellitus and heart failure with reduced ejection fraction: The CANA-HF study. <i>Diabetes/Metabolism Research and Reviews</i> , 2020 , 36, e3335	7.5	10
45	Lack of soluble circulating cardiodepressant factors in takotsubo cardiomyopathy. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2017 , 208, 170-172	2.4	10
44	Carvedilol increases blood pressure response to phenylephrine infusion in heart failure subjects with systolic dysfunction: evidence of improved vascular alpha1-adrenoreceptor signal transduction. <i>American Heart Journal</i> , 2008 , 156, 315-21	4.9	10
43	C-Reactive Protein and N-Terminal Pro-brain Natriuretic Peptide Levels Correlate With Impaired Cardiorespiratory Fitness in Patients With Heart Failure Across a Wide Range of Ejection Fraction. <i>Frontiers in Cardiovascular Medicine</i> , 2018 , 5, 178	5.4	10
42	Predicting therapeutic response in patients with heart failure: the story of C-reactive protein. <i>Expert Review of Cardiovascular Therapy</i> , 2015 , 13, 153-61	2.5	9
41	Leukocyte activity in patients with ST-segment elevation acute myocardial infarction treated with anakinra. <i>Molecular Medicine</i> , 2014 , 20, 486-9	6.2	9
40	Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 1635-1654	15.1	9
39	Pharmacologic and surgical interventions to improve functional capacity in heart failure. <i>Heart Failure Clinics</i> , 2015 , 11, 117-24	3.3	8
38	Increased C-reactive protein is associated with the severity of thoracic radiotherapy-induced cardiomyopathy. <i>Cardio-Oncology</i> , 2020 , 6, 2	2.8	7
37	Combination therapy with beta-adrenergic receptor antagonists and phosphodiesterase inhibitors for chronic heart failure. <i>Pharmacotherapy</i> , 2008 , 28, 1523-30	5.8	7
36	The 2017 American College of Cardiology/American Heart Association hypertension guideline and opportunities for community pharmacists. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2018 , 58, 382-386	1.7	7
35	Clinical predictors of response to anakinra in patients with heart failure. <i>International Journal of Cardiology</i> , 2014 , 173, 537-9	3.2	6
34	Right ventricular systolic dysfunction in patients with reperfused ST-segment elevation acute myocardial infarction. <i>International Journal of Cardiology</i> , 2012 , 155, 314-6	3.2	6
33	Targeting the NLRP3 inflammasome in cardiovascular diseases.. <i>Pharmacology & Therapeutics</i> , 2021 , 236, 108053	13.9	6

32	Potential role for interleukin-1 in the cardio-renal syndrome. <i>European Journal of Heart Failure</i> , 2019 , 21, 385-386	12.3	5
31	Interleukin-10 in patients with ST-segment elevation myocardial infarction. <i>International Journal of Cardiology</i> , 2014 , 172, e6-8	3.2	5
30	Meta-analysis of clinical outcomes of PCSK9 modulators in patients with established ASCVD. <i>Pharmacotherapy</i> , 2021 ,	5.8	5
29	Interleukin-1 blockade with Anakinra and heart failure following ST-segment elevation myocardial infarction: results from a pooled analysis of the VCUART clinical trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 ,	6.4	5
28	Determinants of Cardiorespiratory Fitness in Patients with Heart Failure Across a Wide Range of Ejection Fractions. <i>American Journal of Cardiology</i> , 2020 , 125, 76-81	3	5
27	Impact of a pharmacist-physician collaborative care model on time-in-therapeutic blood pressure range in patients with hypertension. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2020 , 3, 404-409	1.4	4
26	Educational Outcomes Resulting From Restructuring a Scholarship Course for Doctor of Pharmacy Students. <i>American Journal of Pharmaceutical Education</i> , 2019 , 83, 7246	2.5	3
25	Edema Index Predicts Cardiorespiratory Fitness in Patients With Heart Failure With Reduced Ejection Fraction and Type 2 Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2021 , 10, e018631	6.31	3
24	A phase 1 clinical trial of SP16, a first-in-class anti-inflammatory LRP1 agonist, in healthy volunteers. <i>PLoS ONE</i> , 2021 , 16, e0247357	3.7	3
23	Safety and Preliminary Efficacy of Lorcaserin for Cocaine Use Disorder: A Phase I Randomized Clinical Trial. <i>Frontiers in Psychiatry</i> , 2021 , 12, 666945	5	3
22	Use of novel antithrombotic agents for COVID-19: Systematic summary of ongoing randomized controlled trials. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 3080-3089	15.4	3
21	Clinical trial enrollment at a rural satellite hospital during COVID-19 pandemic. <i>Journal of Clinical and Translational Science</i> , 2021 , 5, e136	0.4	3
20	Levosimendan in Advanced Heart Failure: Where Do We Stand?. <i>Journal of Cardiovascular Pharmacology</i> , 2018 , 71, 127-128	3.1	2
19	Response to letter regarding article, "targeting interleukin-1 in heart disease". <i>Circulation</i> , 2014 , 130, e63	16.7	2
18	Limited value of brain natriuretic peptide as a prognostic marker in acute heart failure--a meta-analysis. <i>International Journal of Cardiology</i> , 2010 , 145, 540-1	3.2	2
17	Effect of interleukin-1 blockade with anakinra on leukocyte count in patients with ST-segment elevation acute myocardial infarction.. <i>Scientific Reports</i> , 2022 , 12, 1254	4.9	2
16	Blocking Interleukin-1 as a Novel Therapeutic Strategy for Secondary Prevention of Cardiovascular Events 2012 , 26, 217		2
15	Efficacy of different doses of omega-3 fatty acids on cardiovascular outcomes: rationale and design of a network meta-analysis. <i>Minerva Cardioangiologica</i> , 2020 , 68, 47-50	1.1	2

14	Response to Comment on Buckley et al. Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP. <i>Diabetes Care</i> 2017;40:1733-1738. <i>Diabetes Care</i> , 2018 , 41, e86-e87	14.6	2
13	Effect of a Physician/Pharmacist Collaborative Care Model on Time in Target Range for Systolic Blood Pressure: Post Hoc Analysis of the CAPTION Trial. <i>Hypertension</i> , 2021 , 78, 966-972	8.5	2
12	Noninvasive Hemodynamic Monitoring of Cocaine-Induced Changes in Cardiac Output and Systemic Vascular Resistance in Subjects With Chronic Cocaine Use Disorder. <i>Journal of Cardiovascular Pharmacology</i> , 2019 , 74, 528-534	3.1	1
11	The Chronic Kidney Disease Phenotype of HFpEF: Unique Cardiac Characteristics. <i>American Journal of Cardiology</i> , 2021 , 142, 143-145	3	1
10	Diastolic Dysfunction Contributes to Impaired Cardiorespiratory Fitness in Patients with Lung Cancer and Reduced Lung Function Following Chest Radiation. <i>Lung</i> , 2021 , 199, 403-407	2.9	1
9	Pericarditis Recurrence After Initial Uncomplicated Clinical Course. <i>American Journal of Cardiology</i> , 2021 , 160, 112-116	3	1
8	Influence of extracellular volume fraction on peak exercise oxygen pulse following thoracic radiotherapy.. <i>Cardio-Oncology</i> , 2022 , 8, 1	2.8	0
7	Interleukin-1 blockade in cardiac sarcoidosis: study design of the multimodality assessment of granulomas in cardiac sarcoidosis: Anakinra Randomized Trial (MAGiC-ART). <i>Journal of Translational Medicine</i> , 2021 , 19, 460	8.5	0
6	Could recruiting former college athletes be the answer to less pharmacy student burnout?. <i>Currents in Pharmacy Teaching and Learning</i> , 2020 , 12, 357-362	1.5	0
5	Time of eating and cardiorespiratory fitness in patients with heart failure with preserved ejection fraction and obesity. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021 , 31, 2471-2473	4.5	0
4	Preservation of Cardiac Reserve and Cardiorespiratory Fitness in Patients With Acute De Novo Versus Acute on Chronic Heart Failure With Reduced Ejection Fraction. <i>American Journal of Cardiology</i> , 2021 , 158, 74-80	3	0
3	Colchicine in stable chronic heart failure. <i>JACC: Heart Failure</i> , 2014 , 2, 538	7.9	
2	Effect of Canagliflozin Compared With Sitagliptin on Serum Lipids in Patients with Type 2 Diabetes Mellitus and Heart Failure with Reduced Ejection Fraction: A Post-Hoc Analysis of the CANA-HF Study. <i>Journal of Cardiovascular Pharmacology</i> , 2021 , 78, 407-410	3.1	
1	Heart failure clinical trial enrollment at a rural satellite hospital.. <i>Contemporary Clinical Trials</i> , 2022 , 115, 106731	2.3	